Moleculin Biotech Announces Preliminary Results from MIRACLE Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 30 2026
0mins
Moleculin Biotech announced preliminary unblinded efficacy results from the first 45 patients enrolled in Part A of the company's pivotal Phase 2/3 MIRACLE trial, analyzed on a full intent-to-treat basis with no patient exclusions. Both Annamycin treatment arms demonstrated favorable efficacy trends compared with the control arm in patients with relapsed or refractory acute myeloid leukemia. The interim analysis demonstrated a clear efficacy advantage for both Annamycin treatment arms, 190 mg/m plus HiDAC and 230 mg/m plus HiDAC, over the HiDAC control arm. CR reached 43% and 36% in the respective Annamycin cohorts, compared with 12% for control, while CRc reached 50% and 57%, respectively, versus 29% for the control arm. The n=45 population contained 75.6% over 60 years of age, 55.6% 7+3 and 31.1% venetoclax regimens for first line therapies. Importantly, the remission rates for all three arms, including the control arm, reflect outcomes measured after only a single cycle of therapy, as specified by the MIRACLE protocol. The most commonly cited historical benchmarks in this setting, including the MIRROS and CLASSIC I studies, as well as Moleculin's own MB-106 study, permitted multiple cycles of treatment. The company therefore expected absolute remission rates for both the control and Annamycin arms in this single-cycle interim analysis to be lower than those reported in such multi-cycle datasets and believes the most meaningful comparison is the performance of the Annamycin arms relative to the concurrent, randomized control arm evaluated on the same single-cycle basis.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MBRX
Wall Street analysts forecast MBRX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.400
Low
20.00
Averages
24.33
High
31.00
Current: 2.400
Low
20.00
Averages
24.33
High
31.00
About MBRX
Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Moleculin Biotech Reports Preliminary Results from Phase 2/3 Trial
- Clinical Trial Progress: Moleculin Biotech's pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia shows positive preliminary efficacy trends from the first 45 patients, potentially supporting further research.
- Market Opportunity Analysis: CEO Walter Klemp highlighted during the investor segment that market research indicates a significant potential market for Annamycin, which could provide substantial commercial opportunities if approved, further driving company growth.
- R&D Pipeline Update: Moleculin is also developing WP1066, an immune/transcription modulator capable of inhibiting oncogenic transcription factors, targeting brain tumors and pancreatic cancer, showcasing the company's diversified strategy in cancer treatment.
- Future Financing Needs: Despite the optimistic preliminary results, the company requires significant additional financing to support its clinical trials, with no current commitments, posing challenges for future development.
See More
Moleculin Biotech's Clinical Trial Data Triggers Stock Plunge
- Clinical Trial Results: In the ongoing MIRACLE trial, the Annamycin combination with high-dose chemotherapy achieved complete remission rates of 36% to 43%, significantly higher than the 12% seen with standard chemotherapy, indicating potential efficacy in treating relapsed or refractory acute myeloid leukemia (AML), despite lacking statistical significance.
- Stock Reaction: Shares of Moleculin Biotech (MBRX) plummeted over 25% following the announcement of interim data, marking the largest single-day drop since February, reflecting investor concerns regarding the trial's sample size and the company's cash position, leading to a sharp decline after four consecutive days of gains.
- Cash Position: As of the end of the latest reported quarter, MBRX had $10.317 million in cash and cash equivalents, with expectations that funds will last into the third quarter of 2026; however, investor doubts about how the company will secure additional funding for the study may impact future fundraising efforts.
- Market Sentiment: Despite the stock's decline, retail sentiment around MBRX on Stocktwits remained in the 'extremely bullish' territory with high message volume, indicating ongoing investor interest in the company's future potential, with some users suggesting that a partnership with major pharmaceutical companies could provide a significant boost for MBRX.
See More
Moleculin Biotech Reports Positive Interim Results for Annamycin in AML Trial
- Clinical Trial Results: Moleculin Biotech's pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia has shown positive interim efficacy results, with complete remission rates of 43% and 35% in the Annamycin cohorts compared to 12% in the control group.
- Composite Remission Rates: The composite complete remission (CRc) rates for Annamycin were 50% and 57%, significantly outperforming the control group's 29%, indicating a clear therapeutic advantage, particularly among the older patient demographic.
- Trial Progression: The Independent Data Monitoring Committee (iDMC) reviewed the interim data and recommended the trial continue without modification, suggesting that Annamycin's safety and efficacy profile has been preliminarily validated, thereby bolstering the company's confidence as the trial advances.
- Market Performance Analysis: Although MBRX shares are currently trading at $2.56, down 28.25% year-to-date, the positive developments in the MIRACLE trial may attract investor interest, especially as the company continues to enroll participants in the trial.
See More
Moleculin Biotech Reports Positive Preliminary Results for Annamycin in AML Trial
- Significant Efficacy: In the MIRACLE trial, both Annamycin dose arms achieved complete remission (CR) rates of 43% and 36%, significantly outperforming the control arm's 12%, indicating its potential in treating relapsed or refractory acute myeloid leukemia (R/R AML).
- Improved Composite Remission Rates: The composite complete remission (CRc) rates for Annamycin were 50% and 57%, compared to 29% for the control, suggesting that Annamycin's efficacy in a single treatment cycle may surpass historical benchmarks, potentially transforming treatment paradigms.
- Trial Progressing Well: The MIRACLE trial's Part A has enrolled 67 patients, achieving approximately 74% of the target, laying a solid foundation for subsequent dose selection and trial advancement, reflecting the company's proactive clinical development efforts.
- Optimistic Clinical Outlook: Although the preliminary analysis did not achieve statistical significance, the Independent Data Monitoring Committee (iDMC) found a clear efficacy trend favoring Annamycin, supporting the continuation of the trial and indicating the drug's significant potential in R/R AML treatment.
See More
Moleculin Biotech's Annamycin Shows Strong Potential in AML Treatment
- High Prescribing Likelihood: Oncologists reported an average likelihood-to-prescribe score of 6 out of 7 for Annamycin, indicating strong enthusiasm for its potential in treating acute myeloid leukemia (AML), particularly for deep remissions and bridging to transplants.
- Significant Unmet Need: Despite advancements in targeted therapies, the survey revealed that R/R AML patients face substantial treatment gaps, especially those without actionable mutations, suggesting Annamycin's broad applicability could address this unmet need.
- Notable Safety Advantage: Physicians highlighted Annamycin's reduced cardiotoxicity as a critical differentiator, enabling the possibility of repeat dosing, which is particularly relevant for pediatric AML patients concerned about long-term survivorship due to traditional anthracycline limitations.
- Strong Payer Support: Insights from hospital administrators and insurers indicate that Annamycin's efficacy and safety profile are recognized, suggesting it could provide a compelling value proposition for a broad patient population, thereby enhancing its market acceptance.
See More
Moleculin Biotech Advances in AML Trial
- Clinical Trial Progress: Moleculin Biotech announced the enrollment of the 45th subject in its pivotal Phase 2B/3 MIRACLE trial, marking the final preparation phase for interim data unblinding expected in mid-2026, which could represent a significant inflection point for the company.
- Drug Development Outlook: Annamycin, the company's lead program, aims to treat relapsed or refractory acute myeloid leukemia (R/R AML) and is designed to avoid multidrug resistance mechanisms while reducing cardiotoxicity, indicating strong clinical potential.
- FDA Support: Following a successful Phase 1B/2 study, Moleculin believes it has substantially de-risked the development pathway towards potential approval for Annamycin, with future filings contingent on FDA feedback.
- Diverse Product Pipeline: In addition to Annamycin, Moleculin is developing drugs like WP1066 and WP1122 targeting brain tumors, pancreatic cancer, and pathogenic viruses, showcasing the company's broad focus in oncology and virology.
See More
Moleculin Biotech Reports Preliminary Results from Phase 2/3 Trial
- Clinical Trial Progress: Moleculin Biotech's pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia shows positive preliminary efficacy trends from the first 45 patients, potentially supporting further research.
- Market Opportunity Analysis: CEO Walter Klemp highlighted during the investor segment that market research indicates a significant potential market for Annamycin, which could provide substantial commercial opportunities if approved, further driving company growth.
- R&D Pipeline Update: Moleculin is also developing WP1066, an immune/transcription modulator capable of inhibiting oncogenic transcription factors, targeting brain tumors and pancreatic cancer, showcasing the company's diversified strategy in cancer treatment.
- Future Financing Needs: Despite the optimistic preliminary results, the company requires significant additional financing to support its clinical trials, with no current commitments, posing challenges for future development.
See More
Moleculin Biotech's Clinical Trial Data Triggers Stock Plunge
- Clinical Trial Results: In the ongoing MIRACLE trial, the Annamycin combination with high-dose chemotherapy achieved complete remission rates of 36% to 43%, significantly higher than the 12% seen with standard chemotherapy, indicating potential efficacy in treating relapsed or refractory acute myeloid leukemia (AML), despite lacking statistical significance.
- Stock Reaction: Shares of Moleculin Biotech (MBRX) plummeted over 25% following the announcement of interim data, marking the largest single-day drop since February, reflecting investor concerns regarding the trial's sample size and the company's cash position, leading to a sharp decline after four consecutive days of gains.
- Cash Position: As of the end of the latest reported quarter, MBRX had $10.317 million in cash and cash equivalents, with expectations that funds will last into the third quarter of 2026; however, investor doubts about how the company will secure additional funding for the study may impact future fundraising efforts.
- Market Sentiment: Despite the stock's decline, retail sentiment around MBRX on Stocktwits remained in the 'extremely bullish' territory with high message volume, indicating ongoing investor interest in the company's future potential, with some users suggesting that a partnership with major pharmaceutical companies could provide a significant boost for MBRX.
See More
Moleculin Biotech Reports Positive Interim Results for Annamycin in AML Trial
- Clinical Trial Results: Moleculin Biotech's pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia has shown positive interim efficacy results, with complete remission rates of 43% and 35% in the Annamycin cohorts compared to 12% in the control group.
- Composite Remission Rates: The composite complete remission (CRc) rates for Annamycin were 50% and 57%, significantly outperforming the control group's 29%, indicating a clear therapeutic advantage, particularly among the older patient demographic.
- Trial Progression: The Independent Data Monitoring Committee (iDMC) reviewed the interim data and recommended the trial continue without modification, suggesting that Annamycin's safety and efficacy profile has been preliminarily validated, thereby bolstering the company's confidence as the trial advances.
- Market Performance Analysis: Although MBRX shares are currently trading at $2.56, down 28.25% year-to-date, the positive developments in the MIRACLE trial may attract investor interest, especially as the company continues to enroll participants in the trial.
See More
Moleculin Biotech Reports Positive Preliminary Results for Annamycin in AML Trial
- Significant Efficacy: In the MIRACLE trial, both Annamycin dose arms achieved complete remission (CR) rates of 43% and 36%, significantly outperforming the control arm's 12%, indicating its potential in treating relapsed or refractory acute myeloid leukemia (R/R AML).
- Improved Composite Remission Rates: The composite complete remission (CRc) rates for Annamycin were 50% and 57%, compared to 29% for the control, suggesting that Annamycin's efficacy in a single treatment cycle may surpass historical benchmarks, potentially transforming treatment paradigms.
- Trial Progressing Well: The MIRACLE trial's Part A has enrolled 67 patients, achieving approximately 74% of the target, laying a solid foundation for subsequent dose selection and trial advancement, reflecting the company's proactive clinical development efforts.
- Optimistic Clinical Outlook: Although the preliminary analysis did not achieve statistical significance, the Independent Data Monitoring Committee (iDMC) found a clear efficacy trend favoring Annamycin, supporting the continuation of the trial and indicating the drug's significant potential in R/R AML treatment.
See More
Moleculin Biotech's Annamycin Shows Strong Potential in AML Treatment
- High Prescribing Likelihood: Oncologists reported an average likelihood-to-prescribe score of 6 out of 7 for Annamycin, indicating strong enthusiasm for its potential in treating acute myeloid leukemia (AML), particularly for deep remissions and bridging to transplants.
- Significant Unmet Need: Despite advancements in targeted therapies, the survey revealed that R/R AML patients face substantial treatment gaps, especially those without actionable mutations, suggesting Annamycin's broad applicability could address this unmet need.
- Notable Safety Advantage: Physicians highlighted Annamycin's reduced cardiotoxicity as a critical differentiator, enabling the possibility of repeat dosing, which is particularly relevant for pediatric AML patients concerned about long-term survivorship due to traditional anthracycline limitations.
- Strong Payer Support: Insights from hospital administrators and insurers indicate that Annamycin's efficacy and safety profile are recognized, suggesting it could provide a compelling value proposition for a broad patient population, thereby enhancing its market acceptance.
See More
Moleculin Biotech Advances in AML Trial
- Clinical Trial Progress: Moleculin Biotech announced the enrollment of the 45th subject in its pivotal Phase 2B/3 MIRACLE trial, marking the final preparation phase for interim data unblinding expected in mid-2026, which could represent a significant inflection point for the company.
- Drug Development Outlook: Annamycin, the company's lead program, aims to treat relapsed or refractory acute myeloid leukemia (R/R AML) and is designed to avoid multidrug resistance mechanisms while reducing cardiotoxicity, indicating strong clinical potential.
- FDA Support: Following a successful Phase 1B/2 study, Moleculin believes it has substantially de-risked the development pathway towards potential approval for Annamycin, with future filings contingent on FDA feedback.
- Diverse Product Pipeline: In addition to Annamycin, Moleculin is developing drugs like WP1066 and WP1122 targeting brain tumors, pancreatic cancer, and pathogenic viruses, showcasing the company's broad focus in oncology and virology.
See More
